Home Newsfeeds Oppenheimer Downgrades CinCor Pharma to Perform

Oppenheimer Downgrades CinCor Pharma to Perform

Oppenheimer analyst Jay Olson downgrades CinCor Pharma (NASDAQ:CINC) from Outperform to Perform.

byBenzinga Newsdesk

November 29, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades CinCor Pharma (NASDAQ:CINC) from Outperform to Perform.

P/E Ratio Insights for Charter Communications

By Benzinga Insights

April 5, 12:15 PM

In the current market session, Charter Communications Inc. (NASDAQ:CHTR) price is at $352.75, after a 1.33% spike. However,…

CHTR

Churchill Downs Analyst Sized Up ‘High-Quality Kentucky Derby Asset’: Project Pipeline Includes Casinos

By Chris Katje

October 3, 12:07 PM

Renowned for owning the Churchill Downs racetrack and hosting the iconic Kentucky Derby annually, Churchill Downs Inc (NASDAQ: CHDN) also boasts an impressive portfolio of other

CHDN

Mizuho Downgrades Adobe to Neutral, Lowers Price Target to $440

By Benzinga Newsdesk

September 12, 6:16 AM

Mizuho analyst Gregg Moskowitz downgrades Adobe (NASDAQ:ADBE) from Buy to Neutral and lowers the price target from $480 to $440.

ADBE

News

Walmart Health Expands Access To Affordable Care In Florida With Ambetter From Sunshine Health And Orlando Health Collaborations

By Benzinga Newsdesk

November 1, 2:49 PM

Walmart Health is entering into a relationship with Ambetter from Sunshine Health, which provides insurance to individuals through the Florida health insurance marketplace, and with Orlando Health, a private,

CNC

Oppenheimer Downgrades CinCor Pharma to Perform

Related Posts

P/E Ratio Insights for Charter Communications

Churchill Downs Analyst Sized Up ‘High-Quality Kentucky Derby Asset’: Project Pipeline Includes Casinos

Mizuho Downgrades Adobe to Neutral, Lowers Price Target to $440

Walmart Health Expands Access To Affordable Care In Florida With Ambetter From Sunshine Health And Orlando Health Collaborations